# A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

> **NCT02924688** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2436 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** FF/UMEC/VI (100/31.25/25) mcg
- **DRUG:** FF/UMEC/VI (100/62.5/25) mcg
- **DRUG:** FF/UMEC/VI (200/31.25/25) mcg
- **DRUG:** FF/UMEC/VI (200/62.5/25) mcg
- **DRUG:** FF/VI (100/25) mcg
- **DRUG:** FF/VI (200/25) mcg
- **DRUG:** Fluticasone/salmeterol (FSC)
- **DRUG:** Albuterol/salbutamol
- **DEVICE:** ELLIPTA DPI
- **DEVICE:** DISKUS DPI
- **DEVICE:** METERED-DOSE INHALER (MDI)

## Key facts

- **NCT ID:** NCT02924688
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-13
- **Primary completion:** 2019-02-22
- **Final completion:** 2019-02-22
- **Target enrollment:** 2436 (ACTUAL)
- **Last updated:** 2021-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02924688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02924688, "A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02924688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*